环泊酚用于全身麻醉或镇静患者的疗效及安全性的系统评价再评价OA

OBJECTIVE:To summarize and evaluate the existing systematic reviews/Meta-analyses(SR/MA)evidence for comparison of ciprofol and propofol through the re-assessment of systematic review methods,so as to provide evidence-based guidance for clinical medication.METHODS:English and Chinese databases such as PubMed,Embase,the Cochrane Library,and CNKI were systematically searched to identify relevant SR/MA of comparison of ciprofol and propofol for general anesthesia or sedation(with a search period from database establishment to Nov.30th,2024).Methodological quality was assessed by using A Measurement Tool to Assess Systematic Reviews(AMSTAR 2),evidence certainty was graded via the Grading of Recommendations Assessment,Development and Evaluation(GRADE)tool.Overlap of primary studies was calculated,and core outcome measures were summarized.RESULTS:Fifteen SR/MA were included.Methodological quality assessment of AMSTAR 2 revealed 3 high-quality literature,while most literature had critical flaws.GRADE evaluation indicated low or very low certainty for most efficacy and safety evidence.Overlap analysis demonstrated high redundancy among primary studies(correct overlapping areas=0.17).Results showed comparable efficacy between ciprofol and propofol in sedation success rates,with ciprofol exhibiting advantages in reducing injection pain,improving patient satisfaction,and enhancing respiratory safety,partial indicators had relatively high evidence quality.Inconsistent findings were observed in hemodynamic events and intraoperative movement control,lacking robust evidence.CONCLUSIONS:Current evidence suggests that ciprofol offers superior safety in specific aspects compared with propofol while maintaining equivalent efficacy for patients undergoing general anesthesia or sedation.However,the overall low quality of included studies and regional concentration limit the generalizability of findings.High-quality primary research and SR are warranted to enhance evidence reliability and clinical applicability.